Influence of structure on release profile of acyclovir loaded polyurethane nanofibers: Monolithic and core/shell structures

Electrospun fiber patches for inflammatory skin diseases - Correlating in vitro drug release with ex vivo permeation

In this proof-of-concept study, we aimed to develop an anti-inflammatory patch that in contrast to the semi-solid standard therapy is dry and non-greasy, and only needs to be changed once a day due to continuous release of the active ingredient over 24 h. While fiber materials for the treatment of inflammatory skin diseases have been reported in the literature, the majority of studies focuses solely on material characterization including in vitro release studies; however, there is a lack of ex vivo permeation studies as well as comparison with standard therapy. However, such experiments are crucial to deduct the potential efficacy of the drug delivery system, as skin absorption of the drug may be the rate-limiting step and not the drug release. Therefore, we set out to investigate different types of electrospun fiber systems based on polycaprolactone, a polymer with a well-established safety profile widely used for fabricating electrospun patches. The electrospun fiber patches were loaded with the anti-inflammatory drug hydrocortisone and characterized not only for their drug release properties, but for the first time also for their skin permeation and retention as well as their cytocompatibility and anti-inflammatory properties on human skin. While in the release studies, the layer-by-layer fiber system proved to be best suited for an application time of 24 h, this was not reflected in the permeation studies, where all fiber systems showed a similar skin permeation and retention of the drug. In our study set-up, a comparison with standard cream formulations revealed that electrospun fibers offer an advantage in terms of the permeated amount of hydrocortisone. Overall, this study supports the importance of conducting comparisons with standard therapies and, additionally, confirms that electrospun fibers are a promising dosage form for the controlled release of anti-inflammatory drugs for the treatment of inflammatory skin diseases.

Electrospun fibers for the treatment of skin diseases

Skin diseases are among the most common diseases in the global population and with the growth of the aging population, they represent an increasing burden to healthcare systems worldwide. Even though they are rarely life-threatening, the suffering for those affected is high due to the visibility and physical discomfort related to these diseases. Typical symptoms of skin diseases include an inflamed, swollen or itchy skin, and therefore, there is a high demand for effective therapy options. In recent years, electrospinning has attracted considerable interest in the field of drug delivery. The technique allows producing multifunctional drug-loaded fibrous patches from various natural and synthetic polymers with fiber diameters in the nano- and micrometer range, suitable for the treatment of a wide variety of skin diseases. The great potential of electrospun fiber patches not only lies in their tunable drug release properties and the possibility to entrap a variety of therapeutic compounds, but they also provide physical and mechanical protection to the impaired skin area, exhibit a high surface area, allow gas exchange, absorb exudate due to their porous structure and are cytocompatible and biodegradable. In the case of wound healing, cell adhesion is promoted due to the resemblance of the electrospun fibers to the structure of the native extracellular matrix. This review gives an overview of the potential applications of electrospun fibers in skin therapy. In addition to the treatment of bacterial, diabetic and burn wounds, focus is placed on inflammatory diseases such as atopic dermatitis and psoriasis, and therapeutic options for the treatment of skin cancer, acne vulgaris and herpes labialis are discussed. While we aim to emphasize the great potential of electrospun fiber patches for the treatment of skin diseases with this review paper, we also highlight challenges and limitations of current research in the field.

Acyclovir in the Treatment of Herpes Viruses – A Review

Background:

Herpes Simplex (HSV) viruses are widely spread, highly contagious human pathogens. The statistics indicate that 50-90% of adults worldwide are seropositive for these viruses, mainly HSV-1 and HSV-2. The primary infection results in the appearance of watery blisters (cold sores) on the skin, lips, tongue, buccal mucosa or genitals. The ocular infection is the major cause of corneal blindness in the Western World. Once the HSV virus enters human body, it cannot be completely eradicated because HSV viruses are able to change into their latent form which can survive the treatment. The viron resides in trigeminal ganglia of the host, who becomes vulnerable to the reoccurrence of the disease during the whole lifespan. The neurotropic and neuro-invasive properties of HSV are responsible for neurodegenerative illnesses, such as Alzheimer's disease. Acyclovir and its analogues, being the inhibitors of the viral DNA replication, are the only approved medicines for HSV infection therapies.

Objective:

The current paper presents the up-to-date overview of the important pharmacological features of acyclovir, its analogues and their delivery systems including the mechanism of action, routes of administration, absorption and metabolism, as well as side effects of the therapy.

Conclusion:

Acyclovir remains the gold standard in the treatment of herpes virus infections, mainly due to the emerging of the new delivery systems improving considerably its bioavailability. The analogues of acyclovir, especially their esters, characterized by significantly higher bioavailability and safety, may gradually replace acyclovir in selected applications.

Oxidized chitosan modified electrospun scaffolds for controllable release of acyclovir

Developing a novel scaffold carrier with a sustained and controllable release profile of drug is essential to promote the effective transdermal delivery for acyclovir (ACY). In this work, electrospun polyacrylonitrile nanofibers (PAN NFs) was chemically modified with oxidized chitosan (OC). The modified fibrous scaffold was further loaded with the ACY for drug released investigation. FT-IR and NMR results revealed that the conversion of the functional group for each step has successfully occurred on the surface of the fibers. Through the in-vitro drug release and kinetic study, it demonstrated that ACY could be sustainably and controlled released from the OC modified scaffold following the Korsmeyer-Peppas model with a Fickian diffusion mechanism. The human adipose-derived stem cells and the blood combability evaluation confirmed the obtained scaffold possessed excellent cell biocompatibility and hemocompatibility. It could be concluded that the resultant OC modified scaffold based on electrospun PAN NFs opened a new potential option for the topical/transdermal drug delivery of ACY.

Polymeric Electrospun Fibrous Dressings for Topical Co-delivery of Acyclovir and Omega-3 Fatty Acids

Herpetic infections caused by Herpes simplex virus (HSV) are among the most common human infections, affecting more than two quarters of the world's population. The standard treatment for orofacial herpes is the administration of antiviral drugs, mainly acyclovir (ACV). However, current products are mostly based on semisolid formulations that have limited ability to promote drug skin penetration and tend to leak from the application site, thus showing reduced ability to sustain local drug residence. This work reports on the production of poly (ε-caprolactone) (PCL) fibrous matrices with ACV and omega-3 fatty acids (ω3) for application as dressings to the topical treatment of orofacial herpes. PCL fibrous matrices with the co-incorporated bioactive compounds were obtained by electrospinning and characterized regarding their morphology, chemical, physical, and mechanical properties. The potential use of the developed polymeric fibrous matrices for topical applications was evaluated by: (i) the release kinetics of the bioactive compounds; (ii) the occlusive factor of the fibrous mat; (iii) ACV skin permeation capacity; and (iv) the cytotoxicity in a keratinocyte cell line. PCL fibrous matrices loaded with the bioactive compounds presented a smooth morphology and a good balance between flexibility and hardness essential to be durable for handling, while having a desirable texture to be used comfortably. The fibrous mat also provided a sustained release of ACV during 96 h and improved the skin permeability of this drug (Kp = 0.00928 ± 0.000867 cm/h) presenting also high porosity (74%) and a water vapor transmission rate (WVTR) of 881 ± 91 g/m²day, essential to maintain moist and oxygen for faster healing of herpes lesions. Furthermore, cytotoxicity studies suggest that the fibrous mat are safe for topical application. Overall, the PCL based electrospun fibrous matrices with ACV and ω3 hereby described have the potential to be used as therapeutic bandage systems for the treatment of orofacial herpes.